ReviewInflammation2013
CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus.
Review in Inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Adjuvant Probiotics ofFrontiers in endocrinology · 2022Trial
- Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease.Scientific reports · 2015Trial
- Predictive Biomarkers for Coronary Collateral Circulation Development After Myocardial Infarction.International journal of molecular sciences · 2026Review
- Integrative bioinformatics-machine learning-experimental validation identifies shared immunomodulatory targets in psoriasis and psoriatic arthritis and deciphers allicin's therapeutic mechanism.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- JAK inhibitors: a new choice for diabetes mellitus?Diabetology & metabolic syndrome · 2025Review
- Regulatory role of microRNAs in virus-mediated inflammation.Journal of inflammation (London, England) · 2024Review
- Clinical importance of cytokine (IL-6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetes.Scientific reports · 2024Article
- Serum Mediators in Patients with Both Type 2 Diabetes Mellitus and Pruritus.Acta dermato-venereologica · 2023Article
- IFNβ-InducedInternational journal of molecular sciences · 2022Article
- Neuroinflammatory and Neurometabolomic Consequences From Inhaled Wildfire Smoke-Derived Particulate Matter in the Western United States.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- Association between fatigue and cytokine profiles in patients with ischemic stroke.Frontiers in neurology · 2022Article
- Review
- Malaria parasites both repress host CXCL10 and use it as a cue for growth acceleration.Nature communications · 2021Article
- Serum levels of CC chemokine ligands in cutaneous leishmaniasis patients.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Article
- Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/CXCR3 Axis: A Review.Oman medical journal · 2020Review
- Differences in Interleukin-8 Plasma Levels between Diabetic Patients and Healthy Individuals Independently on Their Periodontal Status.International journal of molecular sciences · 2018Article
- Neonatal hyperglycemia induces CXCL10/CXCR3 signaling and microglial activation and impairs long-term synaptogenesis in the hippocampus and alters behavior in rats.Journal of neuroinflammation · 2018Article
- Early Cutaneous Leishmaniasis Patients Infected With Leishmania braziliensis Express Increased Inflammatory Responses After Antimony Therapy.The Journal of infectious diseases · 2018Article
- CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients.Journal of biomedical research · 2017Article
- Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology of the most autoimmune disorders is largely yet to be understood. However, major target antigens have been determined against some of clinically important molecules of human autoimmune diseases, such as insulin in type 1 diabetes mellitus (T1DM). T1DM is believed to be resulted from immune-mediated destruction of insulin-producing β-cells in pancreatic islets of Langerhans. Chemokines are small glycoproteins (weighing 8-10 kDa) that are chemotactive for a wide variety of cell types especially immune system cells and their target cells express appropriate G protein receptors. CXCL10 is a 10-kDa protein and is functionally categorized as an "inflammatory" chemokine. Recently, accumulating reports have shown that the serum and/or the tissue expressions of CXCL10 are increased in various autoimmune diseases like T1DM. Thus, in this article we will focus on the crucial role(s) played by CXCL10 in pathogenesis of T1DM. Therefore, we tried our best to collect the current reports regarding relationship between the serum concentrations of CXCL10 in T1DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.